Lynch CC - Search Results

1

EphA2 Is a Clinically Relevant Target for Breast Cancer Bone Metastatic Disease.

Vaught DB, Merkel AR, Lynch CC, Edwards J, Tantawy MN, Hilliard T, Wang S, Peterson T, Johnson RW, Sterling JA, Brantley-Sieders D. Vaught DB, et al. Among authors: lynch cc. JBMR Plus. 2021 Mar 9;5(4):e10465. doi: 10.1002/jbm4.10465. eCollection 2021 Apr. JBMR Plus. 2021. PMID: 33869989 Free PMC article.

2

MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL.

Lynch CC, Hikosaka A, Acuff HB, Martin MD, Kawai N, Singh RK, Vargo-Gogola TC, Begtrup JL, Peterson TE, Fingleton B, Shirai T, Matrisian LM, Futakuchi M. Lynch CC, et al. Cancer Cell. 2005 May;7(5):485-96. doi: 10.1016/j.ccr.2005.04.013. Cancer Cell. 2005. PMID: 15894268 Free article.

3

Tie2 signaling regulates osteoclastogenesis and osteolytic bone invasion of breast cancer.

Min Y, Ren X, Vaught DB, Chen J, Donnelly E, Lynch CC, Lin PC. Min Y, et al. Among authors: lynch cc. Cancer Res. 2010 Apr 1;70(7):2819-28. doi: 10.1158/0008-5472.CAN-09-1915. Epub 2010 Mar 16. Cancer Res. 2010. PMID: 20233869 Free PMC article.

4

Osteoclast-derived matrix metalloproteinase-9 directly affects angiogenesis in the prostate tumor-bone microenvironment.

Bruni-Cardoso A, Johnson LC, Vessella RL, Peterson TE, Lynch CC. Bruni-Cardoso A, et al. Among authors: lynch cc. Mol Cancer Res. 2010 Apr;8(4):459-70. doi: 10.1158/1541-7786.MCR-09-0445. Epub 2010 Mar 23. Mol Cancer Res. 2010. PMID: 20332212 Free PMC article.

5

2010 Young Investigator Award winner: Therapeutic aprotinin stimulates osteoblast proliferation but inhibits differentiation and bone matrix mineralization.

Schoenecker J, Mignemi N, Stutz C, Liu Q, Edwards J, Lynch C, Holt G, Schwartz H, Mencio G, Hamm H. Schoenecker J, et al. Spine (Phila Pa 1976). 2010 Apr 20;35(9):1008-16. doi: 10.1097/BRS.0b013e3181d3cffe. Spine (Phila Pa 1976). 2010. PMID: 20407341

6

An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment.

Thiolloy S, Edwards JR, Fingleton B, Rifkin DB, Matrisian LM, Lynch CC. Thiolloy S, et al. Among authors: lynch cc. PLoS One. 2012;7(1):e29862. doi: 10.1371/journal.pone.0029862. Epub 2012 Jan 4. PLoS One. 2012. PMID: 22238668 Free PMC article.

7

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo.

Lwin ST, Fowler JA, Drake MT, Edwards JR, Lynch CC, Edwards CM. Lwin ST, et al. Among authors: lynch cc. Mol Cancer. 2017 Feb 28;16(1):49. doi: 10.1186/s12943-017-0616-9. Mol Cancer. 2017. PMID: 28241871 Free PMC article.

8

An integrated computational model of the bone microenvironment in bone-metastatic prostate cancer.

Araujo A, Cook LM, Lynch CC, Basanta D. Araujo A, et al. Among authors: lynch cc. Cancer Res. 2014 May 1;74(9):2391-401. doi: 10.1158/0008-5472.CAN-13-2652. Cancer Res. 2014. PMID: 24788098 Free PMC article.

9

Current and emerging therapies for bone metastatic castration-resistant prostate cancer.

Frieling JS, Basanta D, Lynch CC. Frieling JS, et al. Among authors: lynch cc. Cancer Control. 2015 Jan;22(1):109-20. doi: 10.1177/107327481502200114. Cancer Control. 2015. PMID: 25504285 Free PMC article. Review.

10

Predictive computational modeling to define effective treatment strategies for bone metastatic prostate cancer.

Cook LM, Araujo A, Pow-Sang JM, Budzevich MM, Basanta D, Lynch CC. Cook LM, et al. Among authors: lynch cc. Sci Rep. 2016 Jul 14;6:29384. doi: 10.1038/srep29384. Sci Rep. 2016. PMID: 27411810 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters